|

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

RECRUITINGPhase 2Sponsored by University of California, San Diego
Actively Recruiting
PhasePhase 2
SponsorUniversity of California, San Diego
Started2024-02-20
Est. completion2026-08-20
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT05787639

Summary

The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, resulting in dramatic response in HPV (Human Papilloma Virus) virus related cancers of the throat. This trial will leverage targeted tumor radiation and immunotherapy in advance of standard surgical therapy to improve the response of HPV (Human Papilloma Virus) throat cancer to radiation and immunotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed diagnosis of Stage I T1-2N1M0 HPVOPC (Human Papilloma Virus Oropharynx Cancer)
* Amenable to surgical resection
* Are able to safely receive neoadjuvant radiation and Evorpacept/Pembrolizumab

Exclusion Criteria:

• Patients with solitary lymph nodes less than 3 cm

Conditions2

CancerOropharynx Cancer

Locations3 sites

California

1 site
UC San Diego Moores Cancer Center
La Jolla, California, 92093

Oregon

2 sites
Providence Health & Services
Portland, Oregon, 97213
George Morris503-215-1979canrsrchstudies@providence.org
Oregon Health and Science University
Portland, Oregon, 97239
Teresa Wilsonwilstere@ohsu.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.